Attention Bias Modification in Depression: A Randomized Trial Using a Novel, Reward-based, Eye-tracking Approach
Overview
Psychiatry
Social Sciences
Affiliations
Background And Objectives: Biased attention to negative information is a mechanism for risk and relapse in depression. Attentional bias modification (ABM) paradigms manipulate attention away from negative information to reduce this bias. ABM results have been mixed due to inconsistent methodologies and stimuli design. This randomized controlled trial used a novel approach to modifying attentional bias.
Methods: An eye tracker manipulated stimuli in response to participants' fixations to preferentially reward attention to positive stimuli by obscuring or enhancing image quality of negative and positive stimuli, respectively. Participants with major depressive disorder completed three 35-min sessions of active (n = 20) or sham (n = 20) ABM training. Attentional bias, memory for emotional words, and mood were assessed pre- and post-training.
Results: Training reduced negative attentional bias; relative to sham, active training participants focused significantly more on positive compared to negative stimuli in a free-viewing eye-tracker task (p = .038, η = 0.109) and, at trend, disengaged from sad information more quickly in a computerized task (p = .052, η = 0.096). Active training participants remembered more happy than sad words in an emotional word learning task, indicating a distal transfer of training to emotional memory (p = .036, η = 0.11). Training did not significantly affect mood in the one-week trial.
Limitations: Future studies should build on this proof-of-principle study with larger sample sizes and more intensive treatment to explore which mechanisms of training may lead to improvements in mood.
Conclusions: Attention biases in depression are modifiable through reward-based, eye-tracking training. These data suggest generalizability of training to other cognitive faculties - recall for affective information.
Gillespie K, Dymond A, Li X, Schweitzer D, Branjerdporn G, Khan S J Clin Med. 2024; 13(15).
PMID: 39124616 PMC: 11312778. DOI: 10.3390/jcm13154348.
Bjertrup A, Kofoed J, Egmose I, Wendelboe K, Southgate V, Vaever M Trials. 2024; 25(1):478.
PMID: 39010232 PMC: 11247870. DOI: 10.1186/s13063-024-08316-1.
Imbert L, Neige C, Moirand R, Piva G, Bediou B, Vallet W Sci Rep. 2024; 14(1):12000.
PMID: 38796509 PMC: 11127986. DOI: 10.1038/s41598-024-62251-4.
Yang R, Zheng H, Cao X, Mo D, Li M, Liu W Front Psychiatry. 2024; 15:1352971.
PMID: 38563026 PMC: 10983793. DOI: 10.3389/fpsyt.2024.1352971.
Soldini A, Vogelmann U, Aust S, Goerigk S, Plewnia C, Fallgatter A Eur Arch Psychiatry Clin Neurosci. 2024; .
PMID: 38407625 DOI: 10.1007/s00406-024-01759-2.